Organs-on-Chips Market

Global Organs-On-Chips Market Size

The global organ on a chip market, valued at USD 100 million in 2025, is projected to reach USD 129 million in 2026 and USD 944 million by 2035, with a 24.8% CAGR during the forecast period 2026 to 2035. 

To learn more about this report, request a free sample copy

The new research study consists of industry trends, detailed market analysis, partnerships and collaborations analysis, funding and investment trends, patent analysis, grant analysis, brand positioning analysis and market impact analysis; the report also includes market forecast and opportunity analysis.

According to research, in the US, only 1 out of 1,000 potential drugs progresses to clinical trials post preclinical testing. Of these, 90% of the drugs fail during clinical trials, primarily due to the lack of efficacy or unforeseen toxicity. This high failure rate can be attributed to the inability of animal based preclinical models to accurately predict human responses, since they may not fully recreate the complex human biology / mechanisms. Therefore, to address this issue and ultimately reduce the economic burden on healthcare due to drug failures in clinical trials, several stakeholders are seeking alternative testing methods to overcome the increasing limitations associated with animal testing. One such innovation is the organ-on-a-chip technology, which mimics human physiological functions in a controlled in-vitro microfluidic environment. The adoption of these advanced models in drug discovery and ADME toxicology testing is steadily increasing, offering lucrative potential in improving the success rates of drugs in clinical trials.

Till date, several pharmaceutical manufacturers, and academic and research institutions have increasingly embraced the utilization of in vitro models that mimic in vivo conditions for drug discovery and toxicity testing. This shift is further supported by initiatives from regulatory bodies such as the USFDA and the U.S. Environmental Protection Agency (EPA), aimed at reforming the drug approval process and reducing the reliance on animal testing. As a result, the industry is moving towards more ethical and sustainable alternatives.

Organ-on-chips offers distinct advantages over traditional testing methods, such as enhanced physiological relevance by using human cells instead of animal models, increased in vivo replicability, lower study costs, reduced reliance on animal models, and applicability in personalized medicines by culturing organs using patient-derived stem cells. Further, these products also allow complete control over the research / drug testing models, the reconstruction of specific tissue / organ microenvironment, stable concentration gradients, and the modeling of dynamic mechanical stresses.  Notably, organ-on-chips address challenges in neurological research, such as lack of cell-cell interaction and shear stress associated with blood-brain barrier (BBB) by recreating the complex in vivo environment of the human brain.

Driven by these benefits, several industry stakeholders are launching their proprietary products and technologies to streamline the early-stage evaluation of novel drug interventions across a broad spectrum of disease indications. The various types of organ-on-chip models available currently include lung on a chip, liver on a chip, heart on a chip, brain on a chip and multi organ models. Some companies also offer customized solutions tailored to specific client needs for in vitro testing. In the opinion of Dhriti Gulati, Senior Business Analyst at Roots Analysis “With promising benefits over animal testing, expanding research and development efforts and increasing investor interest, coupled with the growing demand for accurate clinical solutions, the cumulative annual organs-on-chips market growth rate is anticipated to be 25.6% during the forecast period.

Organs-on-Chips Market Segmentation Insights

The market report presents an in-depth analysis of various companies involved in the organ-on-chip industry, across different segments, as defined in the table below:

Organs-on-Chips Market: Report Attributes / Market Segmentations

Key Report Attributes	Details
Historical Trend	Since 2019
Forecast Period	Till 2035
Market Size 2026	$ 129 Million
Market Size 2035	$ 944 Million
CAGR (Till 2035)	24.8%
Type of Product	Organ Based Disease Based
Type of Organ	Single Organ Based  Multi Organ Based
Type of Single Organ based Model	Liver on a Chip Lung on a Chip Brain on a Chip Heart on a Chip Intestine on a Chip Kidney on a Chip Other Organs on Chips
Type of Material	Polydimethylsiloxane Other Polymers Glass Other Materials
Purpose	Research Purpose Therapeutic Purpose
Application Area	Drug Discovery and Toxicity Testing Cancer Research Stem Cell Research Tissue Engineering and Regenerative Medicine
End User	Pharmaceutical and Biotech Companies Academic and Research Players Cosmetic Industry Players Other End Users
Geographical Regions	North America (US, Canada and Rest of North America) Europe (UK, Germany, France, Italy, Spain and Rest of Europe) Asia-Pacific (China, Japan, South Korea, Australia and Rest of Asia-Pacific) Latin America Middle East and North Africa
Leading Market Players in Organs-on-Chips Market	4DCell Aim biotech Beonchip Bi/ond CN BIO Emulate InSphero Jiksak Bioengineering Kirkstall Lena Biosciences Merck Millipore MesoBio Tech MicroBrain Biotech Mimetas Numa Biosciences Qureator SynVivo TissUse Visikol Xona microfluidics
Key Companies Profiled	Aim biotech Beonchip BiomimX CN BIO Draper Dynamic42 Emulate Hesperos InSphero Mimetas NETRI React4life SynVivo TissUse Xona microfluidics (Full list of 45+ companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Market Landscape: Organ-on-Chip Technologies and Models Market Landscape: Organ-on-Chips and Plates Academic Grants Analysis Patent Analysis Partnerships and Collaborations  Funding and Investments Analysis Brand Positioning Analysis: Organ-on-Chip Technologies and Models Brand Positioning Analysis: Organ-on-Chips and Plates Market Forecast and Opportunity Analysis

One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the market for organ on chips, over the forecast period. Based on multiple relevant parameters, adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period till 2035.

The organs-on-chips market analysis also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of product (organ based and disease based), type of organ (single organ based and multi organ based), type of single organ based model (liver, lung, brain, heart, intestine, kidney and other organs), type of material of construction (polydimethylsiloxane, other polymer, glass and others), purpose (research and therapeutic), application area (drug discovery / toxicity testing, cancer research, stem cell research, tissue engineering / regenerative medicine and others), end user (pharmaceutical and biotech companies, academic and research players, cosmetic industry players and other end users), geographical regions (North America (US, Canada and Rest of North America), Europe (UK, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia and Rest of Asia-Pacific), Latin America and Middle East and North Africa and leading players.

In order to account for future uncertainties and to add robustness to our market data model, we have provided three organs-on-chips market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the market. In addition, the research report features detailed transcripts of interviews held with the following industry stakeholders (arranged in decreasing order of seniority level):

• Chief Executive Officer, Small Company, US
• Chief Executive Officer, Mid-sized Company, France
• Chief Executive Officer, Small Company, South Korea
• Chief Executive Officer, Small Company, Italy
• Chief Executive Officer, Small Company, Scotland
• Chief Technology Officer, Mid-sized Company, The Netherlands
• Chief Business Development Officer, Mid-sized Company, France
• President, Mid-sized Company, US

All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Organs-on-Chips Market Share Insights

Market Share by Type of Product

Based on the type of product, the global market for organs-on-chips is segmented into organ based and disease-based models. Organ based models currently capture the highest share (70%) of the organs-on-chips market, owing to the growing demand for organ models (such as lung, liver, brain, heart, intestine, kidney and other organs) for evaluating drug efficacy in preclinical trials and studying organ physiology and drug response. Further, the continuous efforts by stakeholders to develop more advanced and innovative organ-on-chips models contribute to the higher market share of this segment. It is worth mentioning that the disease-based model segment is likely to grow at a higher CAGR (around 27%) in the coming years. Additionally, the organ chips have the potential in effectively studying complex models, such as the blood brain barrier and aid researchers in the development of targeted therapeutics.

Market Share by Type of Organ

Based on the type of organ, the global organs-on-chips market is distributed across single organ and multi organ based models. Currently, organ-on-chip products supporting single organ based models capture the majority (74%) of the overall market share. However, this trend is expected to shift in the coming years as multi-organ based models are expected to grow at a higher CAGR of around 28%, capturing majority of the market share by 2035. This can primarily be attributed to the fact that multi organ based models possess great potential in studying / assessing organ-organ crosstalk and efficiently tracking metabolic pathways across multiple organs. This provides a more accurate and holistic view of the drug responses in disease indications, presenting lucrative opportunity in drug discovery and toxicity testing, making multi-organ based models increasingly attractive to pharmaceutical and research stakeholders.

Market Share by Type of Single Organ based Model

Based on the type of single organ based model, the global market is segmented into liver, lung, brain, heart, intestine, kidney and other organs based models. Currently, liver-on-a-chip models hold the largest market share (25%). However, lung, brain, and heart-on-a-chip models are expected to capture a combined share of more than 50% of the organs-on-chips market by 2035. This can be attributed to their ability to accurately replicate the complex 3D structures of the respective organs in vitro. Further, with the ongoing advancements in organ-on-chip technologies, these models are anticipated to flourish in the coming years.

Market Share by Type of Material

Based on the type of material, the global market value is segmented across polydimethylsiloxane (PDMS), other polymers, glass and other materials. Currently, PDMS is the most preferred material for construction for organ chips, capturing more than 45% of the organs-on-chips market share. This can be attributed to its high flexibility, transparency and gas permeability. However, considering a few disadvantages associated with the use of PDMS, such as leaching out of uncrosslinked oligomers, industry players are actively researching alternative materials of construction for organ chips.

Market Share by Purpose

Based on purpose, the global market is segmented into research and therapeutic purposes. Currently, more than 50% of the organ on a chip market size is dedicated towards research purposes. However, this trend is likely to change in the coming years, due to the potential applications of organ-on-chips across therapeutics purposes. This shift in the trend can be attributed to the increasing demand for treatments targeting cancer, genetic disorders and neurologic diseases. Considering this shift in trends, the organs-on-chips market for therapeutic purposes is estimated to grow at a CAGR of around 27% in the coming decade.

Market Share by Application Area

Based on application area, the global market for organs on chips is distributed across drug discovery and toxicity testing, cancer research, stem cell research and tissue engineering and regenerative medicines. Currently, organ-on-chips market for cancer research holds major share (45%) in the overall market, owing to increasing demand for therapeutic solutions targeting cancer indications. Further, the market for cancer research is expected to grow at a CAGR of around 25.9% and this trend is likely to remain the same in the future as well. It is worth noting that the market for organ-on-chips models used in stem cell research and tissue engineering is expected to grow at higher CAGRs of 26.5% and 26.4%, respectively.

Market Share by End User

Based on end users, the global market is segmented into pharmaceutical and biotech companies, academic and research players, cosmetic industry players, and other end users. Currently, pharmaceutical and biotech companies hold the highest share (69%) in organs-on-chips market. This trend is unlikely to change in the upcoming years due to the increasing demand for animal-free drug development approaches. However, the cosmetic industry is anticipated to grow at a faster CAGR (around 27%) during the forecast period. Additionally, it is worth highlighting that in Europe, organ-on-chips models have witnessed highest adoption in the recent years, driven by the European Union's ban on animal testing in the cosmetic industry. This regulatory push has encouraged the use of more ethical and sustainable testing methods, fueling the adoption of organ-on-chip technology in cosmetics research.

Market Share by Geographical Regions

Based on the type of geographical regions, the global organs-on-chips market value is segmented across North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our projections, North America currently captures 42% of the overall market. However, the market in Europe is expected to grow at a relatively faster pace (CAGR of more than 26%), till 2035. This can be attributed to the increasing number of research and development activities for novel organ-on-chip solutions and the upcoming product approvals in the region (for testing in cosmetic industry amidst the ban on animal-based trials, in Europe).

Organs-On-Chips Market: Key Insights

The “Organs-on-Chips Market (2nd Edition): Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the organ on a chip companies. The market report highlights the efforts of several companies engaged in this rapidly emerging market segment of the organ-on-chip industry. Key takeaways of the market research report are briefly discussed below.

Competitive Landscape of Organ-on-chip Products

The organ-on-chip products are classified under 2 main categories, including organ-on-chip technologies and models and organ-on-chips and plates.

Currently, 75 integrated organ-on-chip technologies and models are available in the market. It is worth mentioning that over 95% of these organ-on-chip technologies and models have applications across drug discovery and toxicity testing. In addition, around 55% of the organ-on-chip technologies and models cater to organ / multi-organ and disease / pathology based studies. Notably, the organs-on-chips market features the presence of over 25 organ-on-chip technology and model providers. Further, the market is characterized by the presence of small players (73%) followed by mid-sized (19%) and large players (8%). It is worth mentioning that more than 50% of the players are headquartered in Europe.

Further, 72 integrated organ-on-chips and plates are currently available in the market. It is worth mentioning that more than 65% of these organ-on-chip products are applicable for both organ based and disease based studies. In addition, over 25% of the organ-on-chips are compatible with brain models. Notably, the organs-on-chips market features the presence of around 25 organ-on-chips and plate providers. Overall, the market is highly fragmented, featuring the presence of small players (80%) followed by mid-sized (16%) and large players (4%). However, as the industry matures and expertise grows, it is expected that the development and application of these models will expand, driving further innovation and growth in the market.

Organs-on-Chips Market Trends: Partnerships and Collaborations on the Rise

Several stakeholders have been forging alliances with other industry / non-industry players for consolidating their portfolios / presence in the organ-on-chip industry. It is worth highlighting that, since 2017, over 80 partnerships have been inked in the industry. Of these, over 60% of the partnerships have been intracontinental agreements. Interestingly, technology / product utilization agreements (nearly 25%) emerged as the most common type of partnership model adopted by the stakeholders in this domain.

Organs-on-Chips Market Trends: Upswing in Funding and Investment Activity

Several stakeholders in this domain are actively raising funds to accelerate the growth of their operations in the organ-on-chip domain. In the last five years, over USD 350 million funding has been raised for organ-on-chip across more than 75 funding instances. Players based in North America have collectively raised around 70% of the total funding. Additionally, most of the funding instances are grants and awards (57%), followed by venture capital (24%). It is worth highlighting that, in September 2021, Emulate raised USD 82 million in a Series E round, led by Northpond Ventures, Peceptive Advisors, recording the largest investment in organ-on-chip industry.

Organs-on-Chips Market Analysis: Cancer Research Applications holds the Largest Market Share

Currently, the organ on a chip market size for cancer research is estimated to be worth USD 35 million, growing at a CAGR of 25.9% during the forecast period. This can be attributed to the fact that cancer cell-based organ-on-chip models have the potential to support the rising demand for cancer therapeutic research. This allows researchers to accurately model the disease in human organs and microenvironment in vitro, thus helping them to gain better understanding of tumor initiation, progression and drug resistance.

Regional Analysis: North America Dominates the Organs-on-Chips Market

Presently, North America captures over 40% of the overall organs-on-chips market share. Driven by the rising interest of stakeholders in improving their prospects of advancement in drug research and development, the market in North America is anticipated to grow at a CAGR of 24.7%, during the forecast period, till 2035. Notable factors that contribute to the region’s dominance in this industry include the presence of several companies (with diverse experience in research and development of organ-on-chips and plates, and technologies and models) and the rising prevalence of chronic diseases, enhanced industrial efforts for drug research and increased public and private fundings in the domain. However, in terms of market growth, the market for organ-on-chip in Europe is likely to grow at a relatively faster pace (26.3%) in the coming years, primarily due to high participation in funding and investments as well as intracontinental collaborations.

Key Organ on Chip Companies

Examples of key players involved in the manufacturing of organ-on-chip (which have also been profiled in this market report; the complete list of companies is available in the full report) include (in alphabetical order) 4DCell, Aim biotech, Beonchip, Bi/ond, CN Bio, Emulate Bio, InSphero, Jiksak Bioengineering, Kirkstall, Lena Biosciences, Merck Millipore, MesoBio Tech, Microbrain Biotech, Mimetas, Numa Biosciences, Qureator, SynVivo, TissUse, Visikol and Xona microfluidics. This global market research report includes an easily searchable database of all the companies that are developing organ-on-chips and plates, technologies and models.

Organs-on-Chips Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:

• A preface providing an introduction to the full report, Organs-on-Chips Market (2nd Edition), till 2035.
• An outline of the systematic research methodology adopted to conduct this study, covering research assumptions, project and forecast methodologies, primary and secondary research approaches, along with the various analytical frameworks utilized / considered in the report.
• An overview of various comprehensive methodologies and frameworks used to forecast and analyze market trends. Further, it discusses the key factors influencing market dynamics and emphasizes the robust quality control framework adopted to ensure transparency and credibility in the insights presented throughout the report.
• A brief context of the economic factors that impact the overall organs-on-chips market, including currency fluctuations, foreign exchange rates, and known trade barriers. In addition, it evaluates the effects of global recession and inflation on the growth of the market, drawing insights from key historical events to inform decision making in the future.
• An executive summary of the insights captured in our research, featuring key takeaways from the current state of the market and its likely evolution in the short to mid-to-long term.
• A general introduction of organ-on-chip, including historical evolution, design, classification, advantages, limitations, applications and future perspectives of organ-on-chips.
• This section provides an overview of the current market landscape of various organ-on-chip technologies and models, based on several relevant parameters, such as type of models (organ based and disease based), compatible tissue / organ (lung, liver, heart, brain and other organs) and application area (stem cell research, cancer research, regenerative medicine / tissue engineering and drug discovery / toxicity testing). Further, the section includes an overview on the landscape of players engaged in this domain, presenting a detailed analysis based on parameters such as year of establishment, company size and location of headquarters. In addition, it highlights the most active players, in terms of the number of organ-on-chip technologies and models offered.
• This section provides an overview of the current market landscape of various organ-on-chips and plates, based on several relevant parameters, such as type of product (organ and disease based), type of model (organ physiology / multi-organ based and disease / pathology based), compatible organs (lung, liver, heart, brain, other organs and multi organs), application area (stem cell research, cancer research, regenerative medicines / tissue engineering, drug discovery / toxicity testing and other applications), material of construction (polymer, glass, silicon and other materials), type of polymer (polydimethylsiloxane, cyclic olefin copolymer, cyclic olefin polymer, polystyrene, polycarbonate, polypropylene and others) and status of development (commercialized and under development). Further, the section includes a list of players engaged in the development of organ-on-chips and plates offered, along with analyses based on their year of establishment, company size and location of headquarters. In addition, it highlights the most active players, in terms of the number of organ-on-chips and plates offered.
• Elaborate profiles of leading players in organs-on-chips market, based in North America. Each profile features a brief overview of the company (including information on their year of establishment, location of headquarters, number of employees, leadership team, and contact details), organ-on-chip portfolio, recent developments and an informed future outlook.
• Elaborate profiles of leading players offering organ-on-chips, based in Europe. Each profile features a brief overview of the company (including information on their year of establishment, location of headquarters, number of employees, leadership team, and contact details), organ-on-chip portfolio, recent developments and an informed future outlook.
• Elaborate profiles of leading players in organs-on-chips market, based in Asia-Pacific. Each profile features a brief overview of the company (including information on their year of establishment, location of headquarters, number of employees, leadership team, and contact details), organ-on-chip portfolio, recent developments and an informed future outlook.
• An in-depth analysis of patents filed / granted till date in the organ-on-chip domain, based on various relevant parameters, such as type of patent, publication year, application year, patent jurisdiction, CPC symbols, type of applicant, patent age, leading inventors, leading industry and non-industry players (in terms of number of patents filed / granted) and patent benchmarking. In addition, the section also features a patent benchmarking analysis and an insightful patent valuation analysis, highlighting the leading patents (in terms of number of citations).
• A detailed brand positioning analysis of the key organ-on-chip technology and model providers, highlighting the current perceptions regarding their proprietary technologies and models by taking into consideration several relevant aspects, such as portfolio strength, portfolio diversity, years of experience, and company size.
• A detailed brand positioning analysis of the key organ-on-chips and plates providers, highlighting the current perceptions regarding their proprietary chips and plates by taking into consideration several relevant aspects, such as portfolio strength, portfolio diversity, years of experience, and company size.
• An in-depth analysis of grants that have been awarded to research institutes in the organ-on-chip domain, based on various relevant parameters, such as year of award, amount awarded, administering institute centre, support period, type of grant application, purpose of grant, activity code, emerging focus area, study section involved, popular NIH departments (in terms of number of grants awarded), type of recipient organization, leading recipient organizations (in terms of number of grants and amount of grants) and location of recipient organization.
• An insightful analysis of the partnerships and collaborations inked by stakeholders in organs-on-chips market, based on several parameters, such as year of partnership, type of partnership, type of organ, geographical regions, purpose of partnership and most active players (in terms of number of partnerships signed). It also provides analysis of geographical distribution of partnership activity.
• A detailed analysis of the funding and investments raised by organ on a chip companies, based on relevant parameters, such as year of funding, type of funding, amount invested (USD million), purpose of funding, associated organ / system, therapeutic area, geographical area, most active players (in terms of number of funding instances and amount raised), most active investors (in terms of number of funding instances) and summary of investments.
• A case study on scaffold-free 3D cell culture products, including hanging drop plate, 3D petri dish, and ultra-low attachment plate, featuring a list of more than 60 products that are being used for research and pharmaceutical testing, based on a number of relevant parameters, such as status of development (commercialized and developed, not commercialized), type of system (suspension system, attachment resistant and microfluidic system), type of product (ultra-low attachment plate, plate, hanging drop plate, chips and dish) and material used for fabrication (chemical / polymer based, human based and plant based).
• An in-depth analysis of the factors that can impact the growth of the organs-on-chips market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
• A detailed estimate of the current market size, opportunity and future growth potential for organ-on-chips over the next decade. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period, till 2035. The report also features the likely distribution of the current and forecasted opportunity within the organs-on-chips market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
• Detailed projections of the current and future opportunity within the organ-on-chip industry across types of products, namely organ based and disease based.
• Detailed projections of the current and future opportunity within the organ-on-chip market across types of organs, namely single organ based and multi organ based.
• Detailed projections of the current and future opportunity within the organs-on-chips market across types of single organ based models, namely liver, lung, brain, heart, kidney, intestine and other organ based models.
• Detailed projections of the current and future opportunity within the market for organ-on-chip across types of material of construction, namely PDMS, other polymers, glass and other materials.
• Detailed projections of the current and future opportunity within the market for organ-on-chip across purposes, namely research and therapeutic purposes.
• Detailed projections of the current and future opportunity within the organs-on-chips market across application areas, namely drug discovery and toxicity testing, cancer research, stem cell research and regenerative medicine and tissue engineering.
• Detailed projections of the current and future opportunity within the organ-on-chip market across end users, namely pharmaceutical and biotech companies, academic and research players, cosmetic industry players and other end users.
• Detailed projections of the current and future opportunity within the organs on chips industry across geographical regions, namely North America (US, Canada and Rest of North America), Europe (UK, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia and Rest of Asia-Pacific) Latin America and Middle East and North Africa.

Recent Developments In The Organs-On-Chips Market

Several recent developments have taken place in the field of organ-on-chip. We have outlined some of these initiatives below.

• In May 2026, Harvard researchers developed the first vagina-on-a-chip, a microfluidic model replicating the human vaginal environment using living cells. The device enables real-time monitoring of hormonal, microbial, and infection responses, offering a more accurate alternative to animal testing and advancing research in women’s health conditions such as bacterial vaginosis.
• In April 2026, NASA entered into a collaboration with Harvard’s Wyss Institute and Emulate with an aim to deploy organ-on-chip devices containing astronauts’ bone marrow cells on the Artemis II mission. The “Avatar” experiment studies radiation and microgravity effects on human biology, aiming to validate chip-based human models for space medicine and broader biomedical applications on Earth.
• In April 2026, Oregon Health & Science University secured over USD 9.2 million in NIH funding to develop next-generation organs-on-chips for bone-related cancers. The project aims to model cancer growth, metastasis, and treatment response in bone tissues, strengthening microphysiological systems for oncology drug development and precision medicine research.
• In February 2026, Dynamic42 launched DynamicOrgan® O2 Sensor Kit, an organ-on-chip platform with integrated real-time oxygen monitoring. The system enables non-invasive measurement of oxygen levels, improving analysis of cellular metabolism, disease progression, and drug responses, thereby addressing a key limitation in advanced in vitro microphysiological models.

Author(s): Debarjun Basak, Dhriti Gulati and Rupanshi Sharma

Frequently Asked Questions

Question 1: What are organs on a chip?

Answer: Organ-on-chips are systems that can mimic organs or human physiological systems in vitro to test drug candidates or study organ or disease physiology.

Question 2: What is the organ-on-a-chip platform?

Answer: Organ-on-chip platform is a platform that uses microfluidic technology to structure organ or disease physiology and provide insights about the applied parameters of experiments.

Question 3: What is the organ-on-a-chip global market?

Answer: The organ-on-chip global market represents the global status of organ-on-chip in terms of its annual growth, current value, categories and applications.

Question 4: How big is the organ-on-chip market?

Answer: The current market size of organ-on-chip is estimated to be USD 129 million.

Question 5: What is the potential organ on a chip market size by 2035?

Answer: The potential organ on a chip market size is estimated to be USD 944 million by 2035.

Question 6: What is the anticipated growth rate for organs-on-chips market?

Answer: The anticipated growth rate of organ-on-chips market is 24.8%.

Question 7: Which region is leading the organs-on-chips market?

Answer: Currently, North America is leading the organ-on-chip market with an estimated market share of around 42%.

Question 8: How big is the liver-on-a-chip market?

Answer: The liver-on-a-chip market currently holds 26% of the overall single organs-on-chips market.

Question 9: What companies are using organ-on-a-chip?

Answer: Various industries that use organ-on-chips are pharmaceutical and biotech companies, academic and research players, cosmetic industry and among other end users as well.

Question 10: Is organ-on-a-chip FDA approved?

Answer: FDA has taken several actions to support organ-on-chips such as FDA Modernization Act 2.0 and research and development agreement with Emulate to test organ-on-chips in FDA laboratories.